New targeted radiation therapy tested for stubborn bone marrow cancer

NCT ID NCT06888323

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a drug called lintuzumab-Ac225 in 18 adults with high-risk myelodysplastic syndrome (MDS) that did not improve after standard treatment. The drug is an antibody that seeks out cancer cells and delivers a radioactive payload to kill them. The main goal is to find a safe dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lintuzumab-Ac225 (a monoclonal antibody linked to a radioactive particle)
What this could lead to: If it works, this could point toward a new treatment option for people with high-risk MDS that hasn't responded to standard therapy.
What could go wrong: This is a very early, small Phase 1 trial (18 people) focused on safety and dosing, not proof of effectiveness. The study is currently suspended, and the radioactive agent may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Dana-Farber - Harvard Cancer Center LAO

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.